Is MacroGenics, Inc. (MGNX) a Buy, Sell, or Hold?
NASDAQ : MGNX
MacroGenics, Inc.
$4.055 USD
-$0.27 (-6.13%)
- Volume
- 588.83K
- Average Volume
- 1.14M
- Market Capitalization
- $257.75M
- P/E Ratio
- -3.93
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $5.08
- Year Low
- $1.29
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.90
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Eric Risser |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | MGNX |
| CUSIP | 556099109 |
| CIK | 0001125345 |
| Web | http://www.macrogenics.com |
| Phone | 301 251 5172 |
| Currency | USD |
| Employees | 293 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.72 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.90 |
| Quick Ratio | 1.80 |
| Cash Ratio | 0.69 |
Sales & Book Value
| Annual Sales | $149.5M |
| Price / Sales | 1.75 |
| Cash Flow | -1.13 |
| Price / Cash Flow | -3.83 |
| Price / Book | 12.93 |
Price Target and Rating
| Average Stock Price Forecast | $6.00 |
| High Stock Price Forecast | $6.00 |
| Low Stock Price Forecast | $6.00 |
| Forecast Upside/Downside | -32.42% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 22 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.18 |
| Trailing P/E Ratio | -3.93 |
| PEG Ratio | 0.03 |
| P/E Growth | 0.03 |
| Net Income | -$74.62M |
| Net Margin | -44.79% |
| Pretax Margin | -45.22% |
| Return on Equity | -147.80% |
| Return on Assets | -32.29% |
Financials Score
| AltmanZ Score | -7.08 |
| Piotroski Score | 3.00 |
| Working Capital | 86.58M |
| Total Assets | 217.87M |
| Ebit | -57.72M |
| Market Cap | 270.46M |
| Total Liabilities | 196.68M |
Poll Results
About MacroGenics, Inc. (NASDAQ:MGNX) Stock
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumor ... s, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
2026-07-02 13:01:09
Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
2026-07-02 09:25:00
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, today announced completion of the sale of MacroGenics' good manufacturing practice (GMP) drug substance manufacturing operations to Bora.
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
2026-06-22 16:43:00
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration's (FDA) accelerated approval of TZIELD® (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). The approval expands the therapeutic potential of TZIELD as a disease-modifying therapy for type 1 diabetes.
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
2026-05-14 16:01:00
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on Wednesday, May 20, 2026 at 10:30 a.m. ET.
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
2026-05-13 18:36:10
MacroGenics (MGNX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.65 per share a year ago.
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
2026-05-13 16:01:00
ROCKVILLE, Md., May 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended March 31, 2026, and highlighted its recent corporate progress.
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
2026-05-11 17:20:43
•MacroGenics to receive $122. 5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora ROCKVILLE, MD, May 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co.
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
2026-05-11 17:20:00
•MacroGenics to receive $122.5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora
Frequently Asked Questions
-
What is the current MacroGenics, Inc. (MGNX) stock price?
-
MacroGenics, Inc.(NASDAQ:MGNX) stock price is $4.055 in the last trading session. During the trading session, MGNX stock reached the peak price of $5.08 while $1.29 was the lowest point it dropped to. The percentage change in MGNX stock occurred in the recent session was --6.13% while the dollar amount for the price change in MGNX stock was -$0.27.
-
MGNX's industry and sector of operation?
-
The NASDAQ listed MGNX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MGNX?
-
Ezio Bonvini | Senior Vice President of Research & Chief Scientific Officer
Thomas Spitznagel | Senior Vice President of Technical Operations
Harish Krishnaswamy | Senior Vice President of Business Development & Portfolio Planning
Jeffrey Stuart Peters | Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer
Beth Smith | Vice President, Controller & Treasurer -
How many employees does MGNX have?
-
Number of MGNX employees currently stands at 293. MGNX operates from 9704 Medical Center Drive, Rockville, MD 20850, US.
-
Link for MGNX official website?
-
Official Website of MGNX is: http://www.macrogenics.com
-
How do I contact MGNX?
-
MGNX could be contacted at phone #301 251 5172 and can also be accessed through its website. MGNX operates from 9704 Medical Center Drive, Rockville, MD 20850, US.
-
How many shares of MGNX are traded daily?
-
The average number of MGNX shares traded daily for last 3 months was 1.14M.
-
What is the market cap of MGNX currently?
-
The market value of MGNX currently stands at $257.75M with its latest stock price at $4.055